SANCTURA

LOE Approaching

trospium chloride

NDAORALTABLET
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9

Clinical Trials (5)

NCT07379827N/ARecruiting

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Started Feb 2026
1,500 enrolled
Schizophrenia
NCT06853171Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

Started Apr 2025
24 enrolled
Psychiatric Disorders
NCT06605950Phase 1Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

Started Oct 2024
78 enrolled
Healthy Volunteers
NCT01178827Phase 4Completed

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Started Aug 2010
20 enrolled
Overactive Bladder
NCT01089751Phase 4Completed

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Started Mar 2010
322 enrolled
Overactive Bladder